Skip to content
The Policy VaultThe Policy Vault

Sprycel (dasatinib) — United Healthcare

Gastrointestinal stromal tumor (GIST) with PDGFRA exon 18 mutations

Initial criteria

  • Diagnosis of gastrointestinal stromal tumor (GIST) with PDGFRA exon 18 mutations

Reauthorization criteria

  • Patient does not show evidence of progressive disease while on Sprycel therapy

Approval duration

12 months